Overview Dividends

(ARDX) Ardelyx - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0396971071

Kidney Drug, Bowel Drug

ARDX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -10.05%
EPS Trend (3Y Correlation): -8.6%

ARDX Revenue

Revenue Growth (3Y CAGR): 39.49%
Revenue Trend (3Y Correlation): 80.5%

Risk via 10d forecast
Volatility	77.1%
Value at Risk 5%th	106%

Reward
Sharpe Ratio	0.09
Alpha	-15.48

Character
Hurst Exponent	0.582
Beta	0.664

Drawdowns 3y
Max DD	66.32%
Mean DD	29.11%

Description: ARDX Ardelyx August 14, 2025

Ardelyx Inc, a biotechnology company listed on NASDAQ under the ticker symbol ARDX, operates in the United States. The companys stock performance and financial health are critical indicators of its potential for growth and return on investment.

From a financial perspective, Ardelyx has a market capitalization of approximately $1.3 billion, indicating a significant presence in the biotechnology sector. However, the companys Price-to-Earnings (P/E) ratio is currently at 0.00, suggesting that it is either not profitable or that its earnings are not being reflected in its stock price. The forward P/E ratio is also 0.00, implying that the market does not expect significant earnings in the near future. The Return on Equity (RoE) stands at -36.57%, indicating that the company is currently not generating profits from shareholders equity.

Key Performance Indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate will be crucial in assessing Ardelyxs financial health and operational efficiency. The companys ability to manage its cash reserves, currently not disclosed, and reduce its cash burn will be vital in sustaining operations and achieving profitability.

Economic drivers for Ardelyx include the demand for its products, particularly in the gastrointestinal and cardio-renal therapeutic areas, where the company is focusing its drug development efforts. The success of its pipeline, including drugs like tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease on dialysis, will be critical. Market competition, regulatory approvals, and pricing pressures will also significantly impact the companys financial performance.

Investors should closely monitor Ardelyxs progress in terms of clinical trial results, FDA approvals, and commercialization of its products. The companys ability to secure partnerships, manage its financial resources effectively, and navigate the complex regulatory landscape will be key determinants of its stock performance.

ARDX Stock Overview

Market Cap in USD	1,472m
Sub-Industry	Biotechnology
IPO / Inception	2014-06-19
Return 12m vs S&P 500	+0.68%
Analyst Rating	4.64 of 5

ARDX Dividends

Currently no dividends paid

ARDX Growth Ratios

CAGR	64.64%
CAGR/Max DD Calmar Ratio	0.97
CAGR/Mean DD Pain Ratio	2.22
Current Volume	2700.7k
Average Volume	3445.2k

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-56.5m TTM) > 0 and > 6% of Revenue (6% = 23.9m TTM)

FCFTA -0.11 (>2.0%) and ΔFCFTA 5.96pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 71.46% (prev 84.81%; Δ -13.35pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.11 (>3.0%) and CFO -53.6m > Net Income -56.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (241.9m) change vs 12m ago 2.54% (target <= -2.0% for YES)

Gross Margin 89.47% (prev 84.76%; Δ 4.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 93.26% (prev 68.46%; Δ 24.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -1.90 (EBITDA TTM -32.5m / Interest Expense TTM 24.5m) >= 6 (WARN >= 3)

Altman Z'' -6.23

(A) 0.59 = (Total Current Assets 368.0m - Total Current Liabilities 83.4m) / Total Assets 486.2m

(B) -1.95 = Retained Earnings (Balance) -946.5m / Total Assets 486.2m

warn (B) unusual magnitude: -1.95 — check mapping/units

(D) -2.85 = Book Value of Equity -946.4m / Total Liabilities 331.9m

Total Rating: -6.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.13

1. Piotroski 2.50pt = -2.50

2. FCF Yield -3.85% = -1.93

3. FCF Margin -13.90% = -5.21

4. Debt/Equity 1.35 = 1.66

5. Debt/Ebitda -5.07 = -2.50

6. ROIC - WACC (= -23.99)% = -12.50

7. RoE -36.91% = -2.50

8. Rev. Trend 80.48% = 6.04

9. EPS Trend -8.58% = -0.43

What is the price of ARDX shares?

As of November 10, 2025, the stock is trading at USD 5.59 with a total of 2,700,679 shares traded.
Over the past week, the price has changed by -5.57%, over one month by +10.47%, over three months by +3.52% and over the past year by +14.20%.

Is Ardelyx a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Ardelyx (NASDAQ:ARDX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 30.13 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARDX is around 5.64 USD . This means that ARDX is currently overvalued and has a potential downside of 0.89%.

Is ARDX a buy, sell or hold?

Ardelyx has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy ARDX.

Strong Buy: 8
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ARDX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	11.4	103.2%
Analysts Target Price	11.4	103.2%
ValueRay Target Price	6.3	11.8%

ARDX Fundamental Data Overview November 02, 2025

Market Cap USD = 1.47b (1.47b USD * 1.0 USD.USD)
P/S = 3.8131
P/B = 9.0672
P/EG = -0.08
Beta = 0.664
Revenue TTM = 398.2m USD
EBIT TTM = -46.4m USD
EBITDA TTM = -32.5m USD
Long Term Debt = 150.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.44m USD (from shortTermDebt, last quarter)
Debt = 207.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 164.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.44b USD (1.47b + Debt 207.6m - CCE 242.7m)
Interest Coverage Ratio = -1.90 (Ebit TTM -46.4m / Interest Expense TTM 24.5m)
FCF Yield = -3.85% (FCF TTM -55.3m / Enterprise Value 1.44b)
FCF Margin = -13.90% (FCF TTM -55.3m / Revenue TTM 398.2m)
Net Margin = -14.20% (Net Income TTM -56.5m / Revenue TTM 398.2m)
Gross Margin = 89.47% ((Revenue TTM 398.2m - Cost of Revenue TTM 42.0m) / Revenue TTM)
Gross Margin QoQ = 98.80% (prev 87.30%)
Tobins Q-Ratio = 2.96 (Enterprise Value 1.44b / Total Assets 486.2m)
Interest Expense / Debt = 2.79% (Interest Expense 5.80m / Debt 207.6m)
Taxrate = -11.76% (negative due to tax credits) (102.0k / -867.0k)
NOPAT = -51.9m (EBIT -46.4m * (1 - -11.76%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.41 (Total Current Assets 368.0m / Total Current Liabilities 83.4m)
Debt / Equity = 1.35 (Debt 207.6m / totalStockholderEquity, last quarter 154.3m)
Debt / EBITDA = -5.07 (negative EBITDA) (Net Debt 164.9m / EBITDA -32.5m)
Debt / FCF = -2.98 (negative FCF - burning cash) (Net Debt 164.9m / FCF TTM -55.3m)
Total Stockholder Equity = 153.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.63% (Net Income -56.5m / Total Assets 486.2m)
RoE = -36.91% (Net Income TTM -56.5m / Total Stockholder Equity 153.2m)
RoCE = -15.28% (EBIT -46.4m / Capital Employed (Equity 153.2m + L.T.Debt 150.9m))
RoIC = -16.19% (negative operating profit) (NOPAT -51.9m / Invested Capital 320.7m)
WACC = 7.80% (E(1.47b)/V(1.68b) * Re(8.46%) + D(207.6m)/V(1.68b) * Rd(2.79%) * (1-Tc(-0.12)))
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 21.57%
Fair Price DCF = unknown (Cash Flow -55.3m)
EPS Correlation: -8.58 | EPS CAGR: -10.05% | SUE: 1.10 | # QB: 1
Revenue Correlation: 80.48 | Revenue CAGR: 39.49% | SUE: 0.81 | # QB: 0

Additional Sources for ARDX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle